On September 30, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Mersana Therapeutics, SEP 30, 2021, View Source [SID1234590577]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Plenary Session Title: Tumor-Targeted Conjugates: A Growing Family
Presentation Title: XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate
Date/Time: Thursday, October 7, 2021 from 12:50 – 2:40 p.m. ET
Presenter: Timothy B. Lowinger, Ph.D., Chief Science & Technology Officer, Mersana Therapeutics

A replay of the webcasted presentation will be available on October 7th after 4 p.m. ET on the Investors & Media section of the Mersana website at www.mersana.com.